CAMBRIDGE, Mass., Oct. 27 /PRNewswire-FirstCall/ -- Biogen Idec Inc. , the world’s third largest biotech company with leading products and capabilities in oncology and immunology, today reported its third quarter 2004 results.
(Logo: http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGO ) Third Quarter Highlights * Revenues were $543 million vs. prior year (adjusted pro forma of $477 million, an increase of 14%), driven primarily by AVONEX(R) (Interferon beta-1a) sales up 16% (adjusted pro forma) to $346 million and RITUXAN(R) (rituximab) co-promotion profits up 19% to $160 million. * On a GAAP basis, earnings per share (EPS) were $0.10; excluding merger- related accounting impacts and other non-operating charges, adjusted pro forma (non-GAAP) EPS were $0.37. * Elan and Biogen Idec announced that the companies have submitted an application to the European Medicines Agency for approval of ANTEGREN(R) (natalizumab) as a treatment for Crohn’s disease. * Sunesis Pharmaceuticals, Inc. and Biogen Idec announced a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. * ImmunoGen, Inc. and Biogen Idec announced that Biogen Idec has licensed exclusive rights to develop and commercialize anti-cancer therapeutics that comprise an antibody developed by Biogen Idec to an undisclosed tumor cell target and ImmunoGen’s proprietary Tumor-Activated Prodrug (TAP) technology. * Biogen Idec announced its Board of Directors has authorized the repurchase of up to 20 million shares of its common stock.
“Since we completed our merger transaction approximately one year ago, Biogen Idec has delivered on its promise,” said James Mullen, Biogen Idec’s Chief Executive Officer. “I applaud the organization for the smooth and rapid integration. We’ve hit our major financial goals, the pipeline has advanced both through in-house efforts and business development deals, and we are on the verge of launching our next product.”
Financial Performance
On an adjusted non-GAAP basis, Biogen Idec reported net income was $132 million in the third quarter of 2004 (Q3 2003: $123 million). Adjusted non- GAAP EPS was $0.37 for the third quarter of 2004 (Q3 2003: $0.35).
Adjusted non-GAAP EPS and net income for the third quarter of 2004 excludes merger-related accounting impacts, such as amortization of intangibles, impairment of intangibles, inventory step up, and other merger- related charges, and other non-operating charges. Adjusted pro forma non-GAAP EPS and net income for the third quarter of 2003 include revenue and expenses from the former Biogen, Inc. from July 1 to September 30, 2003 but excludes other non-operating charges of the former Biogen, Inc. and IDEC
Pharmaceuticals Corporation. These adjustments, expenses, and non-operating charges are itemized on the attached reconciliation tables.
On a reported basis, calculated in accordance with U.S. generally accepted accounting principles (GAAP), Biogen Idec reported net income of $37 million (or EPS of $0.10) in the third quarter of 2004. The difference between adjusted non-GAAP net income and EPS and GAAP net income and EPS in the third quarter was primarily due to $112 million of non-cash merger-related accounting impacts and $13 million write-down of certain investments.
Revenue Performance
Third quarter revenues of AVONEX, Biogen Idec’s therapy for patients with relapsing forms of multiple sclerosis, increased 16% to $346 million (adjusted pro forma Q3 2003: $298 million). U.S. sales were $224 million (adjusted pro forma Q3 2003: $204 million). International sales were $122 million (adjusted pro forma Q3 2003: $94 million); in local currency, sales grew 21%.
Revenues for the third quarter of 2004 included $160 million from Biogen Idec’s joint business arrangement with Genentech, Inc. related to RITUXAN, a treatment for certain B-cell non-Hodgkin’s lymphomas that Biogen Idec co- promotes in the U.S. with Genentech (Q3 2003: $134 million). All U.S. sales of RITUXAN are recognized by Genentech, and Biogen Idec records its share of the pretax co-promotion profits on a quarterly basis. U.S. net sales of RITUXAN in the third quarter of 2004, as recorded by Genentech, were $393 million (Q3 2003: $354 million).
Revenues of ZEVALIN(R) (ibritumomab tiuxetan), Biogen Idec’s radioimmunotherapeutic agent, were $5 million in the third quarter of 2004 (Q3 2003: $4 million).
Revenues of AMEVIVE(R) (alefacept), Biogen Idec’s treatment for moderate- to-severe psoriasis, were $8 million in the third quarter of 2004 (Q3 2003: $12 million).
Royalties were $24 million in the third quarter (adjusted pro forma Q3 2003: $29 million).
Share Repurchase Program
Biogen Idec announced that its Board of Directors has authorized the repurchase of up to 20 million shares of its common stock. The repurchased stock will provide the Company with treasury shares for general corporate purposes, such as stock to be issued under employee stock option and stock purchase plans. The share buyback will be largely funded through operating cash flow and will be accretive to EPS.
William Rastetter, Biogen Idec’s Executive Chairman, said, “This share repurchase plan underscores the belief of management and the Board of Directors that our common stock represents an attractive investment for the Company, based on our well-defined strategy and our prospects for future growth. Given our strong anticipated operating cash flow, we do not expect this program to restrict our strategic flexibility.”
The Company currently has approximately 334 million shares of common stock outstanding.
Recent Highlights * Biogen Idec announced on October 13, 2004, that Health Canada has authorized AMEVIVE for sale in Canada. AMEVIVE, the first biologic approved for psoriasis in Canada, will be marketed for the treatment of patients with moderate-to-severe chronic plaque psoriasis who are candidates for systemic therapy or phototherapy. * On October 6, 2004, ImmunoGen, Inc. and Biogen Idec announced that Biogen Idec licensed exclusive rights to develop and commercialize anti-cancer therapeutics that comprise an antibody developed by Biogen Idec to an undisclosed tumor cell target and ImmunoGen’s proprietary Tumor-Activated Prodrug (TAP) technology. * On September 29, 2004, Elan and Biogen Idec announced that they submitted a Marketing Authorisation Application (MAA) to the European Medicines Agency for the approval of ANTEGREN as a treatment for Crohn’s disease. Additionally, the companies presented new 12-month data from the Phase III maintenance trial, ENACT-2 (Evaluation of Natalizumab As Continuous Therapy-2), at the United European Gastroenterology Week meeting in Prague, Czech Republic, and these data were included in the filing. * On September 7, 2004, Sunesis Pharmaceuticals, Inc. and Biogen Idec announced a collaboration to discover and develop small molecule cancer therapeutics targeting kinases, a family of cell signaling enzymes that play a major role in the progression of cancer. The companies will apply Tethering(R), Sunesis’ proprietary fragment-based drug discovery technology, in an effort to generate novel small molecule leads that inhibit oncology kinase targets. * On August 17, 2004, Biogen Idec and Elan announced that the companies have submitted an application for approval of ANTEGREN as a treatment for multiple sclerosis in Canada, based on one-year data from the ongoing Phase III trials. Conference Call and Webcast
The Company’s earnings conference call for the third quarter will be broadcast via the internet at 5:00 p.m. ET on October 27, 2004, and will be accessible through the investor relations section of Biogen Idec’s homepage, http://www.biogenidec.com/.
About Biogen Idec
Biogen Idec creates new standards of care in oncology and immunology. As a global leader in the development, manufacturing, and commercialization of novel therapies, Biogen Idec transforms scientific discoveries into advances in human healthcare. For product labeling, press releases and additional information about the company, please visit http://www.biogenidec.com/.
Safe Harbor
This press release contains forward-looking statements regarding expected future financial results and plans for our development programs, including ANTEGREN.
These statements are based on the Company’s current beliefs and expectations. A number of risks and uncertainties could cause actual results to differ materially. For example, financial results, including future operating cash flow and overall prospects for growth, may be affected by a number of factors, including any slowing of growth of the markets for AVONEX and RITUXAN, any change in market acceptance of these products in key markets worldwide, the extent to which the Company achieves market acceptance of its other products, the impact of reimbursement and pricing decisions related to the Company’s products, the impact of competitive products on the Company’s products, any material decreases in sales by licensees of products on which the Company receives royalties, the impact of litigation, any unanticipated increase in expenses, in-licensing and product opportunities, increase in costs related to development and commercialization of new products, including ANTEGREN, and any material issues, delays or failures related to the manufacturing or supply of the Company’s products.
Our long-term growth will depend on the successful development and commercialization of new products such as ANTEGREN. Drug development involves a high degree of risk. For example, our plans to launch ANTEGREN as a treatment for MS could be negatively affected if unexpected concerns arise from additional data or analysis, if regulatory authorities require additional information or further studies, or if we were to encounter other unexpected hurdles.
For more detailed information on the risks and uncertainties associated with these forward looking statements and the Company’s other activities see the periodic reports filed by the Company with the Securities and Exchange Commission. The Company does not undertake any obligation to publicly update any forward-looking statements, whether as a result of new information, future events, or otherwise.
Media Contact: Amy Ryan Associate Director, Public Affairs Biogen Idec Tel: (617) 914-6524 Investment Community Contact: Elizabeth Woo Senior Director, Investor Relations Biogen Idec Tel: (617) 679-2812 TABLE 1 Financial Results For The Third Quarter of 2004 Condensed Consolidated Statements Of Income - GAAP Basis (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, 2004 2003 2004 2003 REVENUES Product $359,692 $4,427 $1,095,415 $15,069 Revenue from unconsolidated joint business 159,507 133,960 444,619 363,236 Royalties 23,860 - 73,371 - Corporate partner 217 143 10,377 1,032 Total Revenues 543,276 138,530 1,623,782 379,337 COST AND EXPENSES Cost of product and royalty revenues 64,460 639 470,955 5,282 Research and development 168,889 39,333 498,219 121,384 Selling, general and administrative 132,040 27,157 401,887 74,985 Amortization of acquired intangible assets 107,054 - 267,222 - Total Cost and Expenses 472,443 67,129 1,638,283 201,651 Income (Loss) from Operations 70,833 71,401 (14,501) 177,686 Other income (expense), net (1,573) 1,986 16,566 8,549 INCOME BEFORE INCOME TAXES 69,260 73,387 2,065 186,235 Income taxes 32,492 27,887 5,668 70,769 NET INCOME (LOSS) $36,768 $45,500 $(3,603) $115,466 BASIC EARNINGS (LOSS) PER SHARE $0.11 $0.29 $(0.01) $0.73 DILUTED EARNINGS (LOSS) PER SHARE $0.10 $0.26 $(0.01) $0.67 SHARES USED IN CALCULATING: BASIC EARNINGS (LOSS) PER SHARE 334,777 155,498 335,165 155,117 DILUTED EARNINGS (LOSS) PER SHARE 355,232 184,838 335,165 178,877 TABLE 2 Condensed Consolidated Balance Sheets (dollars in thousands) Sep. 30, 2004 Dec. 31, 2003 Assets: Current assets Cash, cash equivalents and securities available-for-sale $445,880 $835,959 Accounts receivable, net 237,572 198,524 Inventory 246,369 496,349 Other current assets 334,414 307,832 Total current assets 1,264,235 1,838,664 Long-term securities available- for-sale 1,672,126 1,502,327 Property and equipment, net 1,415,689 1,252,783 Intangible assets, net 3,370,624 3,638,812 Goodwill 1,151,105 1,151,066 Other 146,819 120,293 Total assets $9,020,598 $9,503,945 Liabilities and shareholders’ equity Current liabilities $428,601 $404,825 Long-term deferred tax liability 985,672 1,108,318 Non-current liabilities 896,063 937,474 Shareholders’ equity 6,710,262 7,053,328 Total liabilities and shareholders’ equity $9,020,598 $9,503,945 TABLE 3 Condensed Consolidated Statements of Operations and Reconciliation of GAAP Earnings to Adjusted Pro-Forma Non-GAAP Earnings (In millions, except per share data) The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational or unusual activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Numbers may not foot due to rounding. Three Months Ended September 30, 2004 Adjusted GAAP Adjustments Non-GAAP Revenues Product $359.7 - $359.7 Revenue from unconsolidated joint business 159.5 - 159.5 Royalties 23.9 - 23.9 Corporate partner 0.2 - 0.2 Total revenues 543.3 - 543.3 Cost and Expenses Cost of product and royalty revenues 64.5 (3.3) (A) 61.2 Research and development 168.9 (0.1) (B) 168.8 Selling, general and administrative 132.0 (1.7) (B) 130.3 Amortization of acquired intangible assets 107.1 (107.1) (C) - Total costs and expenses 472.4 (112.2) 360.3 Income from operations 70.8 112.2 183.0 Other income (expense), net (1.6) 12.7 (D) 11.2 Income before income taxes 69.3 124.9 194.2 Provision for income taxes 32.5 29.6 (E) 62.1 Net income $36.8 $95.3 $132.0 Numerator: Net Income $36.8 $132.0 Net Income allocable to participating securities ($0.1)(H) ($0.2)(H) Net Income used in calculating basic eps $36.7 $131.8 Net Adjustment for interest expense $0.5 (I) $2.0 Net Income used in calculating diluted eps $37.2 $133.8 Shares used in calculation of earnings per share: Denominator: Weighted average number of common shares outstanding 334.8 334.8 Effect of dilutive securities: stock options, convertible promissory notes 20.5 (I) 29.1 Dilutive potential common shares 355.2 363.9 Earnings per share: Basic $0.11 $0.39 Diluted $0.10 $0.37 column 1 column 2 column 3 = columns 1+2 (A) Represents the non-cash expense related to valuing the inventory acquired from former Biogen, Inc. at fair value. (B) Represents external, incremental consulting, integration costs, severance, and restructuring charges related to the merger. (C) Represents the on-going, non-cash amortization and impairment of acquired intangible assets related to the merger with former Biogen, Inc. (D) Represents $12.7M for the write-down of certain investments. (E) Represents the tax effect of the above adjustments. (F) Represents the elimination of Biogen Idec contract revenue and expense of $3.1M. (G) Represents former Biogen, Inc. operating revenue and expenses for the period Jul-Sep of 2003 prior to the merger, net of intercompany transactions. (H) Due to adoption of EITF 03-06 which requires allocation of income to certain holders of equity & debt instruments. (I) Adjustment for certain interest expense and convertible securities were included in the period as they were dilutive. TABLE 3 Condensed Consolidated Statements of Operations and Reconciliation of GAAP Earnings to Adjusted Pro-Forma Non-GAAP Earnings (In millions, except per share data) The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational or unusual activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Numbers may not foot due to rounding. Three Months Ended September 30, 2003 Adjusted Pro Forma GAAP Adjustments Non-GAAP Revenues Product $4.4 $310.1 (G) $314.5 Revenue from unconsolidated joint business 134.0 - 134.0 Royalties - 28.6 (G) 28.6 Corporate partner 0.1 - 0.1 Total revenues 138.5 338.7 477.2 Cost and Expenses Cost of product and royalty revenues 0.6 54.3 (G) 54.9 Research and development 39.3 87.9 (F), (G) 127.2 Selling, general and administrative 27.2 96.1 (G) 123.3 Amortization of acquired intangible assets - - - Total costs and expenses 67.1 238.3 305.4 Income from operations 71.4 100.4 171.8 Other income (expense), net 2.0 6.9 (G) 8.9 Income before income taxes 73.4 107.3 180.6 Provision for income taxes 27.9 30.0 (G) 57.8 Net income $45.5 $77.4 $122.8 Numerator: Net Income $45.5 $122.8 Net Income allocable to participating securities ($0.6)(H) ($0.8)(H) Net Income used in calculating basic eps $44.9 $122.0 Net Adjustment for interest expense $2.9 $2.9 Net Income used in calculating diluted eps $47.8 $124.9 Shares used in calculation of earnings per share: Denominator: Weighted average number of common shares outstanding 155.5 327.4 Effect of dilutive securities: stock options, convertible promissory notes 29.3 30.3 Dilutive potential common shares 184.8 357.8 Earnings per share: Basic $0.29 $0.37 Diluted $0.26 $0.35 column 4 column 5 column 6 = columns 4+5 (A) Represents the non-cash expense related to valuing the inventory acquired from former Biogen, Inc. at fair value. (B) Represents external, incremental consulting, integration costs, severance, and restructuring charges related to the merger. (C) Represents the on-going, non-cash amortization and impairment of acquired intangible assets related to the merger with former Biogen, Inc. (D) Represents $12.7M for the write-down of certain investments. (E) Represents the tax effect of the above adjustments. (F) Represents the elimination of Biogen Idec contract revenue and expense of $3.1M. (G) Represents former Biogen, Inc. operating revenue and expenses for the period Jul-Sep of 2003 prior to the merger, net of intercompany transactions. (H) Due to adoption of EITF 03-06 which requires allocation of income to certain holders of equity & debt instruments. (I) Adjustment for certain interest expense and convertible securities were included in the period as they were dilutive. TABLE 4 Condensed Consolidated Statements of Operations and Reconciliation of GAAP Earnings to Adjusted Pro-Forma Non-GAAP Earnings (In millions, except per share data) The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational or unusual activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Numbers may not foot due to rounding. Nine Months Ended September 30, 2004 Adjusted GAAP Adjustments Non-GAAP Revenues Product $1,095.4 - $1,095.4 Revenue from unconsolidated joint business 444.6 - 444.6 Royalties 73.4 - 73.4 Corporate partner 10.4 - 10.4 Total revenues 1,623.8 - 1,623.8 Cost and Expenses Cost of product and royalty revenues 471.0 (291.1) (A) 179.9 Research and development 498.2 (3.0) (B) 495.2 Selling, general and administrative 401.9 (6.7) (B) 395.2 Amortization of acquired intangible assets 267.2 (267.2) (C) - Total costs and expenses 1,638.3 (568.0) 1,070.3 Income (loss) from operations (14.5) 568.0 553.5 Other income, net 16.6 12.7 (D) 29.3 Income before income taxes 2.1 580.7 582.8 Provision for income taxes 5.7 180.8 (E) 186.5 Net income (loss) ($3.6) $399.9 $396.3 Numerator: Net Income (Loss) ($3.6) $396.3 Net Income allocable to participating securities - (I) ($0.6)(I) Net Income (Loss) used in calculating basic eps ($3.6) $395.8 Net Adjustment for interest expense - (J) $6.8 Net Income (Loss) used in calculating diluted eps ($3.6) $402.6 Shares used in calculation of earnings (loss) per share: Denominator: Weighted average number of common shares outstanding 335.2 335.2 Effect of dilutive securities: stock options, convertible promissory notes - (J) 31.6 Dilutive potential common shares 335.2 366.8 Earnings (Loss) per share: Basic ($0.01) $1.18 Diluted ($0.01) $1.10 column 1 column 2 column 3 = columns 1+2 (A) Represents the non-cash expense related to valuing the inventory acquired from former Biogen, Inc. at fair value. (B) Represents external, incremental consulting, integration costs, severance, and restructuring charges related to the merger. (C) Represents the on-going, non-cash amortization and impairment of acquired intangible assets related to the merger with former Biogen, Inc. (D) Represents $12.7M for the write-down of certain investments. (E) Represents the tax effect of the above adjustments. (F) Represents the elimination of Biogen Idec contract revenue and expense of $6.3M. (G) Represents former Biogen, Inc. operating revenue and expenses for the period Jan-Sep of 2003 prior to the merger, net of intercompany transactions. (H) Represents former IDEC one-time adjustment of $20M related to a signing payment for the Genentech new anti- CD20 antibody development collaboration. (I) Due to adoption of EITF 03-06 which requires allocation of income to certain holders of equity & debt instruments. (J) Adjustment for certain interest expense and convertible securities were included in the period as they were dilutive. TABLE 4 Condensed Consolidated Statements of Operations and Reconciliation of GAAP Earnings to Adjusted Pro-Forma Non-GAAP Earnings (In millions, except per share data) The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational or unusual activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Numbers may not foot due to rounding. Nine Months Ended September 30, 2003 Adjusted Pro Forma GAAP Adjustments Non-GAAP Revenues Product $15.1 $881.4 (G) $896.5 Revenue from unconsolidated joint business 363.2 - 363.2 Royalties - 100.4 (G) 100.4 Corporate partner 1.0 - 1.0 Total revenues 379.3 981.9 1,361.2 Cost and Expenses Cost of product and royalty revenues 5.3 146.2 (G) 151.5 Research and development 121.4 253.2 (F), (G), (H) 374.6 Selling, general and administrative 75.0 296.4 (G) 371.4 Amortization of acquired intangible assets - - - Total costs and expenses 201.7 695.8 897.5 Income (loss) from operations 177.7 286.1 463.7 Other income, net 8.5 28.2 (G) 36.7 Income before income taxes 186.2 314.2 500.4 Provision for income taxes 70.8 89.3 (G) 160.1 Net income (loss) $115.5 $224.8 $340.3 Numerator: Net Income (Loss) $115.5 $340.3 Net Income allocable to participating securities ($1.6)(I) ($2.2)(I) Net Income (Loss) used in calculating basic eps $113.9 $338.2 Net Adjustment for interest expense $5.5 $7.2 Net Income (Loss) used in calculating diluted eps $119.4 $345.3 Shares used in calculation of earnings (loss) per share: Denominator: Weighted average number of common shares outstanding 155.1 326.4 Effect of dilutive securities: stock options, convertible promissory notes 23.8 30.5 Dilutive potential common shares 178.9 356.9 Earnings (Loss) per share: Basic $0.73 $1.04 Diluted $0.67 $0.97 column 4 column 5 column 6 = columns 4+5 (A) Represents the non-cash expense related to valuing the inventory acquired from former Biogen, Inc. at fair value. (B) Represents external, incremental consulting, integration costs, severance, and restructuring charges related to the merger. (C) Represents the on-going, non-cash amortization and impairment of acquired intangible assets related to the merger with former Biogen, Inc. (D) Represents $12.7M for the write-down of certain investments. (E) Represents the tax effect of the above adjustments. (F) Represents the elimination of Biogen Idec contract revenue and expense of $6.3M. (G) Represents former Biogen, Inc. operating revenue and expenses for the period Jan-Sep of 2003 prior to the merger, net of intercompany transactions. (H) Represents former IDEC one-time adjustment of $20M related to a signing payment for the Genentech new anti- CD20 antibody development collaboration. (I) Due to adoption of EITF 03-06 which requires allocation of income to certain holders of equity & debt instruments. (J) Adjustment for certain interest expense and convertible securities were included in the period as they were dilutive. TABLE 5 Biogen Idec Inc Product Revenues for Third Quarter 2004 (in thousands) The non-GAAP financial measures presented below are utilized by Biogen Idec management to gain an understanding of the comparative financial performance of the Company. Management believes that the non-GAAP financial measures are useful because they exclude those non-operational or unusual activities or transactions that are not necessarily relevant to understanding the trends of the Company or the prospects of future performance. Numbers may not foot due to rounding. Three Months Ended September 30, 2004 2003 Biogen U.S. Revenue Pro Forma U.S. GAAP GAAP Pre- Combined Revenue Revenue merger(a) Revenue PRODUCT REVENUES Avonex(R) $346,248 $- $297,728 $297,728 Amevive(R) 8,222 - 12,381 12,381 Zevalin(R) 5,222 4,427 - 4,427 Total Product Revenues $359,692 $4,427 $310,109 $314,536 Nine Months Ended September 30, 2004 2003 Biogen U.S. Revenue Pro Forma U.S. GAAP GAAP Pre- Combined Revenue Revenue merger(a) Revenue PRODUCT REVENUES Avonex(R) $1,047,482 $- $858,361 $858,361 Amevive(R) 33,325 - 23,074 23,074 Zevalin(R) 14,608 15,069 - 15,069 Total Product Revenues $1,095,415 $15,069 $881,435 $896,504 (a) Represents former Biogen, Inc. revenue that is not included in GAAP revenues.
Photo: http://www.newscom.com/cgi-bin/prnh/20031112/LAW121LOGOAP Archive: http://photoarchive.ap.org/PRN Photo Desk, photodesk@prnewswire.comBiogen Idec Inc.
CONTACT: Media: Amy Ryan, Associate Director, Public Affairs,+1-617-914-6524, or Investment Community: Elizabeth Woo, Senior Director,Investor Relations, +1-617-679-2812, both of Biogen Idec
Web site: http://www.biogenidec.com/
Company News On-Call: http://www.prnewswire.com/comp/101550.html
